Press Releases :: Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

Jul 3, 2023

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

Jun 13, 2023

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

May 22, 2023

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

May 19, 2023

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

May 11, 2023

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

May 4, 2023

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

Mar 29, 2023

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Mar 22, 2023

Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023

Mar 16, 2023

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Mar 7, 2023

Journey Medical Corporation to Participate in the 35th Annual ROTH Conference

rss_feed News RSS